EP2-Jim Joyce-Sigyn Therapeutics-Beyond Statins: Can Cardiodialysis Cut Cardiovascular Risk by 95%?

Welcome to the BioEdge AI Podcast! In this full episode, host Bob sits down with Jim Joyce, Co-Founder, Chairman, and CEO of Sigyn Therapeutics, as he shares his 25-year journey pioneering extracorporeal blood purification technologies. Highlights: • Real-World Impact & Ebola Breakthrough: How Jim's previous company engineered the Hemopurifier—an FDA breakthrough-designated device that cleared over 240 million copies of the Ebola virus from an infected patient in a coma, leading to a full recovery. • Overcoming ICU Trial Bottlenecks: Why traditional ICU clinical trial setups stall life-saving acute therapies, and how Sigyn Therapeutics pivoted to cardiodialysis to conduct executable trials in outpatient dialysis clinics. • Cardiodialysis & Life-Saving Potential: Addressing both cholesterol-promoting lipoproteins and pro-inflammatory molecules during routine dialysis to treat cardiovascular disease in end-stage renal disease patients. Tune in to discover how blood purification is expanding beyond infectious disease into cardiovascular health and oncology platforms like ImmunePrep. Hashtags: #JimJoyce #SigynTherapeutics #BioEdgeAiPodcast #BioEdgeAi #BloodPurification #Cardiodialysis #MedTech #Biotech #CardiovascularHealth